HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.

AbstractBACKGROUND:
Beta blockers have been used widely in the treatment of hypertension and are recommended as first-line drugs in hypertension guidelines. However, a preliminary analysis has shown that atenolol is not very effective in hypertension. We aim to substantially enlarge the data on atenolol and analyse the effect of different beta blockers.
METHODS:
The Cochrane Library and PubMed were searched for beta blocker treatment in patients with primary hypertension. Data were then entered into the Cochrane Collaboration Review Manager package and were summarised in meta-analyses. 13 randomised controlled trials (n=105 951) were included in a meta-analysis comparing treatment with beta blockers with other antihypertensive drugs. Seven studies (n=27 433) were included in a comparison of beta blockers and placebo or no treatment.
FINDINGS:
The relative risk of stroke was 16% higher for beta blockers (95% CI 4-30%) than for other drugs. There was no difference for myocardial infarction. When the effect of beta blockers was compared with that of placebo or no treatment, the relative risk of stroke was reduced by 19% for all beta blockers (7-29%), about half that expected from previous hypertension trials. There was no difference for myocardial infarction or mortality.
INTERPRETATION:
In comparison with other antihypertensive drugs, the effect of beta blockers is less than optimum, with a raised risk of stroke. Hence, we believe that beta blockers should not remain first choice in the treatment of primary hypertension and should not be used as reference drugs in future randomised controlled trials of hypertension.
AuthorsLars Hjalmar Lindholm, Bo Carlberg, Ola Samuelsson
JournalLancet (London, England) (Lancet) 2005 Oct 29-Nov 4 Vol. 366 Issue 9496 Pg. 1545-53 ISSN: 1474-547X [Electronic] England
PMID16257341 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Adrenergic beta-Antagonists
  • Atenolol
Topics
  • Adrenergic beta-Antagonists (therapeutic use)
  • Aged
  • Atenolol (therapeutic use)
  • Blood Pressure (drug effects)
  • Humans
  • Hypertension (complications, drug therapy, mortality)
  • Middle Aged
  • Randomized Controlled Trials as Topic
  • Risk
  • Stroke (etiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: